MENU
+Compare
EVOK
Stock ticker: NASDAQ
AS OF
Apr 3, 01:04 PM (EDT)
Price
$2.47
Change
-$0.12 (-4.63%)
Capitalization
5.17M

EVOK Evoke Pharma, Inc. Forecast, Technical & Fundamental Analysis

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases... Show more

EVOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for EVOK with price predictions
Apr 02, 2025

Momentum Indicator for EVOK turns negative, indicating new downward trend

EVOK saw its Momentum Indicator move below the 0 level on February 27, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In of the 89 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

EVOK moved below its 50-day moving average on February 28, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for EVOK crossed bearishly below the 50-day moving average on March 05, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVOK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for EVOK entered a downward trend on April 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

EVOK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.949) is normal, around the industry mean (60.901). P/E Ratio (0.000) is within average values for comparable stocks, (90.174). EVOK's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.987). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (0.381) is also within normal values, averaging (20.092).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. EVOK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVOK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

View a ticker or compare two or three
EVOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a company which engages in development of drugs to treat gastroenterological disorders and disease

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
420 Stevens Avenue
Phone
+1 858 345-1494
Employees
4
Web
https://www.evokepharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AIXI4.230.22
+5.49%
XIAO-I Corporation
ADIL0.690.03
+5.18%
Adial Pharmaceuticals
ACM95.841.98
+2.11%
Aecom
CCAP17.06-0.07
-0.41%
Crescent Capital BDC
CWT48.50-0.21
-0.43%
California Water Service

EVOK and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, EVOK has been loosely correlated with RDHL. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if EVOK jumps, then RDHL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVOK
1D Price
Change %
EVOK100%
-5.82%
RDHL - EVOK
33%
Loosely correlated
-3.92%
NBIX - EVOK
28%
Poorly correlated
+1.22%
EOLS - EVOK
26%
Poorly correlated
+1.92%
SIGA - EVOK
25%
Poorly correlated
+0.36%
PRFX - EVOK
25%
Poorly correlated
+2.68%
More